Recent Updates — HALO
On September 22, 2026, Halozyme Therapeutics, Inc. completed the sale of $1,500.0 million aggregate principal amount of 1.50% Convertible Senior Notes due 2033, including a $200.0 million option exercise by initial purchasers. The company received net proceeds of approximately $1,471.1 million after deducting discounts and offering expenses. Approximately $187.5 million was used to fund Capped Call Transactions with an initial cap price of $208.39 per share to mitigate potential dilution. Additionally, the company intends to use a portion of the net proceeds to repurchase approximately $151.7 million of its 0.25% convertible senior notes due 2027 and $220.0 million of its 1.00% convertible senior notes due 2028, with total estimated repurchase costs of approximately $652.5 million including accrued interest. The remaining proceeds are designated for general corporate purposes, including working capital, capital expenditures, potential acquisitions, and strategic transactions. Halozyme Therapeutics operates in the biotechnology industry, focusing on drug delivery technologies and oncology treatments.
On September 17, 2026, Halozyme Therapeutics priced a $1.3 billion private offering of convertible senior notes due 2033 with a 1.50% coupon and an initial conversion price of approximately $139.84 per share. The company granted purchasers a 13-day option to buy up to an additional $200 million in notes. Net proceeds are estimated at $1.275 billion, or $1.471 billion if the option is exercised. Halozyme intends to use approximately $652.5 million of these proceeds to repurchase its outstanding 2027 and 2028 convertible notes concurrently with the pricing. The remaining funds will support general corporate purposes, including capped call transactions costing roughly $162.5 million. Halozyme Therapeutics is a biopharmaceutical company specializing in subcutaneous drug delivery technologies.
On September 16, 2026, Halozyme Therapeutics announced a proposed offering of $1.05 billion in aggregate principal amount of convertible senior notes due 2033, with an option to increase the size by up to $150 million. The company intends to use net proceeds to fund capped call transactions and repurchase its existing 0.25% convertible notes due 2027 and 1.00% convertible notes due 2028 through privately negotiated transactions, with remaining funds allocated for general corporate purposes including working capital and potential acquisitions. Halozyme Therapeutics is a biopharmaceutical company specializing in drug delivery technologies, including the ENHANZE platform and auto-injector products.
On August 14, 2026, Halozyme Therapeutics, Inc. announced the election of Dannielle Appelhans to its Board of Directors. Ms. Appelhans was elected to a class of directors with terms ending at the annual meeting in 2028 and was not initially assigned to any board committee. She will receive compensation under the company's standard non-employee director program, including cash retainers, restricted stock, and stock options. The filing confirms there are no arrangements or related person transactions associated with her election. Halozyme Therapeutics operates in the biotechnology industry, focusing on drug delivery technologies.
Halozyme Therapeutics reported second quarter 2026 financial results, posting total revenue of $481 million, a 48% year-over-year increase driven by royalty revenue growth to $307.7 million and product sales. The company raised its full-year 2026 guidance, projecting total revenue between $1.835 billion and $1.910 billion, non-GAAP diluted EPS of $8.65 to $9.00, and adjusted EBITDA of $1.225 billion to $1.280 billion. Halozyme also announced five new collaboration agreements for its ENHANZE and Hypercon technologies with partners including Vertex, GSK, Incyte, and Oruka. Additionally, the company repurchased 4.8 million shares for $332.8 million in the quarter under its existing share repurchase programs. Halozyme Therapeutics is a biopharmaceutical company that develops drug delivery technologies to facilitate subcutaneous administration of therapies.